Stay updated on Safety, PK, and PD of FDL169 in CF - Clinical Trial
Sign up to get notified when there's something new on the Safety, PK, and PD of FDL169 in CF - Clinical Trial page.

Latest updates to the Safety, PK, and PD of FDL169 in CF - Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now presents the study record for the FDL169 cystic fibrosis trial, including its completed Phase 1 status, participant criteria, study locations, and safety and pharmacokinetic measures.SummaryDifference51%

- Check17 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0, while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide notice announces an NIH terminology transition from “Artificial Intelligence” to “Super Intelligence.” It appears above the error page for the study record.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the detailed study record content with a generic error screen. Only the header, footer, and minimal navigation remain, and core study information is no longer accessible.SummaryDifference18%

Stay in the know with updates to Safety, PK, and PD of FDL169 in CF - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety, PK, and PD of FDL169 in CF - Clinical Trial page.